Dizajn, sinteza i evaluacija farmakokinetički relevantnih svojstava novih spirohidantoina izvedenih iz β-tetralona
Bočna strana članka
Glavni sadržaj članka
Apstrakt
U cilju kreiranja novih antikonvulzivnih lekova, sintetisana je serija spirohidantoina izvedenih iz β-tetralona koji u položaju 3 hidantoinskog prstena sadrže 4-supstituisanu benzil-grupu (1a−1g) ili 2-(4-supstituisanu fenil)-2-oksoetil-grupu (2a−2f). Hemijska struktura novosintetisanih molekula potvrđena je određivanjem temperature topljenja, kao i primenom infracrvene spektroskopije sa Furijeovom transformacijom, protonske nuklearne magnetne rezonancije, nuklearne magnetne rezonancije ugljenika-13, UV-vidljive spektroskopije i elementarne analize. Efekat supstituenata na pomeranje apsorpcionih maksimuma jedinjenja 1a−1g i 2a−2f analiziran je Hametovom (Hammett) jednačinom. Uticaj hemijske strukture na farmakološke osobine derivata hidantoina procenjen je primenom "pravila broja pet", Veberovog (Veber), Eganovog (Egan) i Gozovog (Ghose) empirijskog kriterijuma, kao i primenom različitih in silico metoda. U poređenju sa referentnim lekom fenitoinom, derivati koji u svojoj strukturi sadrže atome halogena ili elektron-donorske grupe, trebalo bi da ispoljavaju najbolju intestinalnu apsorpciju i prolazak kroz krvno-moždanu barijeru. U zavisnosti od prirode supstituenta prisutnog u p-položaju fenilnog jezgra, derivati 1a−1g i 2a−2f mogu da budu potencijalni aktivatori/inhibitori pojedinih izoenzima citohroma P450.
Detalji članka
Broj časopisa
Rubrika
Kada je rukopis prihvaćen za objavlјivanje, autori prenose autorska prava na izdavača. U slučaju da rukopis ne bude prihvaćen za štampu u časopisu, autori zadržavaju sva prava.
Na izdavača se prenose sledeća prava na rukopis, uklјučujući i dodatne materijale, i sve delove, izvode ili elemente rukopisa:
- pravo da reprodukuje i distribuira rukopis u štampanom obliku, uklјučujući i štampanje na zahtev;
- pravo na štampanje probnih primeraka, reprint i specijalnih izdanja rukopisa;
- pravo da rukopis prevede na druge jezike;
- pravo da rukopis reprodukuje koristeći fotomehanička ili slična sredstva, uklјučujući, ali ne ograničavajući se na fotokopiranje, i pravo da distribuira ove kopije;
- pravo da rukopis reprodukuje i distribuira elektronski ili optički koristeći sve nosioce podataka ili medija za pohranjivanje, a naročito u mašinski čitlјivoj/digitalizovanoj formi na nosačima podataka kao što su hard disk, CD-ROM, DVD, Blu-ray Disc (BD), mini disk, trake sa podacima, i pravo da reprodukuje i distribuira rukopis sa tih prenosnika podataka;
- pravo da sačuva rukopis u bazama podataka, uklјučujući i onlajn baze podataka, kao i pravo prenosa rukopisa u svim tehničkim sistemima i režimima;
- pravo da rukopis učini dostupnim javnosti ili zatvorenim grupama korisnika na osnovu pojedinačnih zahteva za upotrebu na monitoru ili drugim čitačima (uklјučujući i čitače elektonskih knjiga), i u štampanoj formi za korisnike, bilo putem interneta, onlajn servisa, ili putem internih ili eksternih mreža.
Kako citirati
Reference
Konnert L, Gonnet L, Halasz I, Suppo JS, De Figueiredo RM, Campagne JM, Lamaty F, Martinez J, Colacino E. Mechanochemical preparation of 3,5-Disubstituted hydantoins from dipeptides and unsymmetrical ureas of amino acid derivatives. J Org Chem. 2016; 81: 9802–9809.
Monteiro JL, Pieber B, Corrêa AG, Kappe CO. Continuous synthesis of hydantoins: intensifying the Bucherer-Bergs reaction. Synlett. 2016; 27: 83–87.
Konnert L, Lamaty F, Martinez J, Colacino E. Recent advances in the synthesis of hydantoins: the state of the art of a valuable scaffold. Chem Rev. 2017; 117: 13757–13809.
Czopek A, Zagórska A, Kołaczkowski M, Bucki A, Gryzło B, Rychtyk J, Pawłowski M, Siwek A, Satała G, Bojarski A, Kubacka M, Filipek B. New spirohydantoin derivatives-synthesis, pharmacological evaluation, and molecular modeling study. Acta Pol. Pharm. - Drug Res. 2016; 73: 1545–1554.
Fabíola LC, Diogo VF, Antônia RSP, Mirian GSS, Paula RRS, Charlane KSP, Fagner CL, Márcia RP, Severino AS, Petrônio FAF, Liana CMP, Reinaldo NA. Involvement of proinflammatory cytokines and nociceptive pathways on the pharmacological activity of hydantoin derivative 5-(4-isopropylphenyl)-3-phenyl-imidazolidine-2,4-dione. African J. Pharm. Pharmacol. 2016; 10: 757–765.
Mendes G, Aspesi GH, Arruda ALA, Romanos MTV, Andrade CKZ. In vitro Anti-HMPV activity of new synthetic phenytoin derivatives. J Braz Chem Soc. 2016; 27: 2–9.
Hussain A, Kashif MK, Naseer MM, Rana UA, Hameed S. Synthesis and in vivo hypoglycemic activity of new imidazolidine-2,4-dione derivatives. Res Chem Intermed. 2015; 41: 7313–7326.
Alanazi AM, El-Azab AS, Al-Swaidan IA, Maarouf AR, El-Bendary ER, Abu El-Enin AM, Abdel-Aziz AAM. Synthesis, single-crystal, in vitro antitumor evaluation and molecular docking of 3-substitued 5,5-diphenylimidazolidine-2,4-dione derivatives. Med Chem Res. 2013; 22: 6129–6142.
Ananda Kumar CS, Kavitha CV, Vinaya K, Prasad SBB, Thimmegowda NR, Chandrappa S, Raghavan SC, Rangappa KS. Synthesis and in vitro cytotoxic evaluation of novel diazaspiro bicyclo hydantoin derivatives in human leukemia cells: a SAR study. Invest New Drugs. 2009; 27: 327–337.
Liu J, Zhang K, Mai X, Wei J, Liao Y, Zhong Y, Liu Y, Feng L, Liu C. Synthesis , anticancer evaluation and docking study of 3-benzyloxyhydantoin derivatives. Med Chem. 2016; 12: 37–47.
Czopek A, Byrtus H, Zagórska A, Siwek A, Kazek G, Bednarski M, Sapa J, Pawłowski M. Design, synthesis, anticonvulsant, and antiarrhythmic properties of novel N-Mannich base and amide derivatives of β-tetralinohydantoin. Pharmacol Reports. 2016; 68: 886–893.
Obniska J, Byrtus H, Kamiński K, Pawłowski M, Szczesio M, Karolak-Wojciechowska J. Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins. Bioorganic Med Chem. 2010; 18: 6134–6142.
Scholl S, Koch A, Henning D, Kempter G, Kleinpeter E. The influence of structure and lipophilicity of hydantoin derivatives on anticonvulsant activity. Struct Chem. 1999; 10: 355–366.
Trišović N, Timić T, Divljaković J, Rogan J, Poleti D, Savić MM, Ušćumlić G. Synthesis, structural and biological characterization of 5-phenylhydantoin derivatives as potential anticonvulsant agents, Monatsh Chem. 2012; 143: 1451–1457.
Lazić AM, Božić BĐ, Vitnik VD, Vitnik ŽJ, Rogan JR, Radovanović LD, Valentić NV, Ušćumlić GS. Structure-property relationship of 3-(4-substituted benzyl)-1,3- diazaspiro[4.4]nonane-2,4-diones as new potentional anticonvulsant agents. An experimental and theoretical study. J Mol Struct. 2017; 1127: 88–98.
Vitnik VD, Vitnik ŽJ, Banjac NR, Valentić NV, Ušćumlić GS, Juranić IO. Quantum mechanical and spectroscopic (FT-IR, 13C, 1H NMR and UV) investigations of potent antiepileptic drug 1-(4-chloro-phenyl)-3- phenyl-succinimide. Spectrochim Acta-Part A Mol Biomol Spectrosc. 2014; 117: 42–53.
Milošević NP, Kojić V, Ćurčić J, Jakimov D, Milić N, Banjac N, Ušćumlić G, Kaliszan R. Evaluation of in silico pharmacokinetic properties and in vitro cytotoxic activity of selected newly synthesized N-succinimide derivatives. J Pharm Biomed Anal. 2017; 137: 252–257.
Banjac N, Trišović N, Vitnik Ž, Vitnik V, Valentić N, Ušćumlić G, Juranić I. Solvatochromic and quantum chemical investigations of newly synthesized succinimides: substituent effect on intramolecular charge transfer. Monatsh Chem. 2013; 144: 1525–1535.
Antanasijević D, Antanasijević J, Trišović N, Ušćumlić G, Pocajt V. From classification to regression multitasking QSAR modeling using a novel modular neural network: simultaneous prediction of anticonvulsant activity and neurotoxicity of succinimides. Mol Pharm. 2017; 14; 4476–4484.
Perišić-Janjić N, Kaliszan R, Milošević N, Ušćumlić G, Banjac N. Chromatographic retention parameters in correlation analysis with in silico biological descriptors of a novel series of N-phenyl-3-methyl succinimide derivatives. J Pharm Biomed Anal. 2013; 72: 65–73.
http://www.swissadme.ch/ - pristupljeno 10. 08. 2018.
http://lmmd.ecust.edu.cn./admetsar1/about/ - pristupljeno 10. 08. 2018.
http://www.Openmolecules.org/datawarrior/ - pristupljeno 10. 08. 2018.
http://www.pharmaexpert.ru/passonline/ - pristupljeno 10. 08. 2018.
http://www.compchemcons.com/xlogp/hlogp.html - pristupljeno 10.08.2018
Naydenova E, Pencheva N, Popova J, Stoyanov N, Lazarova M, Aleksiev B. Aminoderivatives of cycloalkanespirohydantoins: synthesis and biological activity. Farmaco. 2002; 57: 189–194.
Suzuki H, Kneller MBB, Rock DA, Jones JP, Trager WF, Rettie AE. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch Biochem Biophys. 2004; 429: 1–15.
Trišović N, Valentić N, Ušćumlić G. Solvent effects on the structure-property relationship of anticonvulsant hydantoin derivatives: a solvatochromic analysis. Chem Cent J. 2011; 5: 1–11.
Lavanya Devi C, Yesudas K, Makarov NS, Jayathirtha Rao V, Bhanuprakash K, Perry JW. Fluorenylethynylpyrene derivatives with strong two-photon absorption: influence of substituents on optical properties. J Mater Chem C. 2015; 3: 3730–3744.
Karelson M, Lobanov VS, Katritzky AR. Quantum-chemical descriptors in QSAR/QSPR studies. Chem Rev. 1996; 96: 1027–1044.
Cohen CN. The molecular modeling perspective in drug design In: Guidebook of Molecular Modeling in Drug Design Ed. Cohen CN, San Diego, California, Acad. Press Inc., 1996: pp. 1–17.
Apostolov S, Vaštag Đ. Proučavanje lipofilnosti potencijalno biološki aktivnih derivata cijanoacetamida. J Eng Process Manag. 2017; 1: 1–9.
Lipinski PJ, Lombardo CA, Dominy F, Feeney BW. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv Drug Deliv Rev. 2012; 64: 4–17.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45: 2615–2623.
Ghose A, Viswanadhan V, Wendoloski J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for Drug Discovery.1. Qualitative and Quantitative Characterization of Known Drug Databases. J Comb Chem. 1999; 1: 55–68.
Egan W, Merz K, Baldwin J. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000; 43: 3867–3877.
Zerroug A, Belaidi S, BenBrahim I, Sinha L, Chtita S. Virtual screening in drug-likeness and structure-activity relationship of pyridazine derivatives as anti-Alzheimer drugs. J King Saud Univ-Sci. (2018). doi:10.1016/j.jksus.2018.03.024.
Wildman SA, Crippen GM. Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci. 1999; 39: 868–873.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46: 3–26.
Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, Will Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci. 2010; 1: 420–434.
Wager TT, Hou X, Verhoest PR, Villalobos A. Central Nervous System Multiparameter Optimization Desirability: application in Drug Discovery. ACS Chem Neurosci. 2016; 7: 767–775.
Wager TT, Hou X, P.R. Verhoest, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci. 2010; 1: 435–449.